IDEXX Laboratories, Inc. — Q2 2021 Form 10-Q Summary
Business context and reporting period
Unaudited results cover the three and six months ended June 30, 2021, compared with the corresponding 2020 periods. IDEXX provides diagnostic products and services primarily to veterinary, livestock, poultry, dairy, water-testing and human medical diagnostics markets. Reportable segments are Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other.
Financial performance and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Total revenue | $826.1 million | $637.6 million | $1.604 billion | $1.264 billion |
| Reported revenue growth | 29.6% | — | 26.9% | — |
| Organic revenue growth | 25.1% | — | 23.1% | — |
| Gross profit / margin | $489.3 million / 59.2% | $379.3 million / 59.5% | $960.1 million / 59.9% | $738.9 million / 58.5% |
| Operating income / margin | $259.3 million / 31.4% | $193.2 million / 30.3% | $506.9 million / 31.6% | $337.6 million / 26.7% |
| Net income attributable to IDEXX | $202.6 million | $148.9 million | $406.8 million | $260.8 million |
| Diluted EPS | $2.34 | $1.72 | $4.69 | $3.01 |
- Q2 revenue increased 29.6%, while net income attributable to IDEXX increased approximately 36.0% and diluted EPS increased approximately 36.0%.
- Six-month revenue increased 26.9%, net income attributable to IDEXX increased approximately 56.0%, and diluted EPS increased approximately 55.8%.
- Six-month operating margin expanded 490 basis points, reflecting volume leverage, pricing and growth in recurring veterinary software, services and diagnostics revenue. Q2 gross margin declined 30 basis points because of instrument mix, moderated laboratory productivity gains and currency-related hedge effects.
- Six-month operating cash flow was $358.4 million, compared with $236.0 million in 2020. Capital expenditures were $42.7 million, and cash paid for acquisitions was $156.5 million.
- Cash and cash equivalents were $232.1 million at June 30, 2021, down from $383.9 million at December 31, 2020. Working capital was $349.4 million versus $480.0 million at year-end.
- Long-term debt, including current maturities, was $905.1 million. The company had no revolving-credit borrowings and $998.6 million of remaining availability under its $1.0 billion unsecured facility, after $1.4 million of letters of credit.
- Trailing-twelve-month adjusted EBITDA was $1.006 billion; gross debt to adjusted EBITDA was 0.91x and net debt to adjusted EBITDA was 0.68x. These are non-GAAP measures.
Material changes versus the prior comparable periods
- CAG revenue rose 31.7% in Q2 and 28.6% for the first six months, with Q2 organic growth of 27.4%. Growth was led by recurring diagnostics, reference laboratory services, consumables, rapid assays and instrument placements.
- Water revenue increased 32.3% in Q2 and 14.4% year to date as testing volumes recovered from pandemic-related disruption.
- LPD revenue increased 4.0% in Q2 and 9.6% year to date, but Q2 organic revenue declined 2.0% due primarily to lower Chinese swine and poultry testing.
- Other revenue declined 11.7% in Q2 because demand for OPTI COVID-19 PCR products and services decreased as vaccination rates increased. Excess COVID-19 testing inventory contributed to product-cost write-downs and reduced Other-segment gross margin.
- Operating expenses increased from pandemic cost-containment levels in 2020, particularly personnel, commercial capability, travel, research and development, and general and administrative costs.
- The company acquired ezyVet and VetRadar assets in Q2 for approximately $157.2 million, including an estimated $5.0 million contingent payment. The preliminary allocation included $109.4 million of goodwill and $42.8 million of identifiable intangible assets.
- Share repurchases totaled $320.8 million in the first six months, compared with $182.8 million in the prior-year period. Q2 repurchases totaled approximately 341,000 shares at an average price of $551.98.
- Cash decreased by $151.8 million in the first six months, primarily because operating cash flow was more than offset by acquisitions, share repurchases and capital expenditures.
Guidance, outlook, risks and unusual items
- The filing does not provide a clear full-year revenue or earnings guidance range. Management increased its 2021 capital-spending outlook to $150 million–$160 million, including approximately $20 million for real estate purchases.
- Management expects lower CAG diagnostic and clinical-visit growth in the second half of 2021 because comparisons will be against the pandemic-related rebound in the second half of 2020.
- Management expects lower LPD revenue in the second half of 2021 due to reduced African Swine Fever testing comparisons in China, rebuilding of swine herds, lower pork prices and changing government requirements.
- Future demand for OPTI COVID-19 testing products and services is expected to be lower, although demand remains difficult to predict because of variants, vaccination rates, testing requirements and competition.
- COVID-19 developments, foreign exchange, supply and operating costs, customer demand, competition and the realizability of customer-program assets remain key uncertainties. A 1% strengthening of the U.S. dollar was estimated to reduce remaining-2021 revenue by approximately $6 million and operating income by approximately $3 million, before specified hedge effects.
- A patent-license royalty lawsuit includes an alleged claim of approximately $50 million. The trial court ruled for the plaintiff; IDEXX is appealing. The company had a $27.5 million accrual established in 2020 and reported no change to that accrual.
- The $50 million 2021 Series A Notes matured and were paid on July 21, 2021. The company expects to repay the $75 million 2022 Series A Notes at maturity using operating cash flow.
- The company was in compliance with its 3.5-to-1 consolidated leverage covenant at June 30, 2021. Management concluded disclosure controls were effective, and reported no material changes to internal control over financial reporting.
Important facts for investors to verify
- Whether elevated CAG growth and veterinary clinical visits normalize materially in the second half of 2021.
- The sustainability of recurring diagnostics volume, pricing, customer retention and instrument-placement trends.
- The extent and timing of the expected LPD decline in China and the continuing decline in OPTI COVID-19 testing demand.
- Integration progress and final purchase-price accounting for ezyVet and VetRadar, including goodwill allocation and contingent consideration.
- Cash deployment among acquisitions, capital expenditures, debt maturities and share repurchases, and the resulting liquidity profile.
- The outcome and potential exposure from the royalty litigation, including any amount above the existing $27.5 million accrual.
- The effect of foreign exchange movements, hedge results, inventory write-downs and other unusual items on reported margins.